# A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults

> **NCT04916795** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Vupanorsen
- **DRUG:** Vupanorsen

## Key facts

- **NCT ID:** NCT04916795
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-17
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-10-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916795, "A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04916795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*